期刊文献+

自拟中药外洗方治疗硼替佐米引起多发性骨髓瘤周围神经病变的影像学分析及临床疗效研究 被引量:5

下载PDF
导出
摘要 目的:分析与评价自拟中药外洗方治疗硼替佐米引起多发性骨髓瘤(MM)周围神经病变(PN)的影像学分析及临床疗效。方法:选择本院于2015年1月—2017年10月间收治的78例硼替佐米引起MM相关PN患者为研究主体。划分为A组和B组,均是39例。A组给予自拟中药外洗方治疗,B组给予甲钴胺片治疗。对比治疗前后的腓神经MNCV(运动神经传导速度)、正中神经MNCV、腓神经SNCV(感觉神经传导速度)、正中神经SNCV与临床疗效。结果:治疗前,对比两组的腓神经MNCV、正中神经MNCV、腓神经SNCV和正中神经SNCV均无差异,无统计学意义(P>0.05)。治疗后,两组的以上指标均升高,且A组高于B组,对比差异显著,有统计学意义(P<0.05)。A组的治疗总有效率为97.44%,B组为74.36%,对比差异明显,有统计学意义(P<0.05)。结论:采用自拟中药外洗方治疗硼替佐米引起MM相关PN可获得较佳的治疗效果,并能改善患者的神经传导速度,应积极推广。
出处 《影像研究与医学应用》 2018年第4期110-111,共2页 Journal of Imaging Research and Medical Applications
  • 相关文献

参考文献7

二级参考文献54

  • 1Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS) : an analysis of the Greek Myeloma Study Group (GMSG). Leukemia,2009, 23 : 1152-1157.
  • 2Conner TM, Doan QD, Waiters IB,et al. An observational, retro- spective analysis of retreatment with bortezomib for muhiple myelo- ma. Clin Lymphoma Myeloma,2008,8 : t40-145.
  • 3Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recom- mendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1. Blood,2011, 117:4691 4695.
  • 4Mohty B, E1-Cheikh J, Yakoub-Agha I,et al, Treatment strategies in relapsed and refractory multiple myeloma: a foeus on drug se-quencing and ' retreatment' approaches in the era of novel agents. Leukemia,2012,26:73-85.
  • 5Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreat- ment in relapsed multiple myeloma-resuhs from a retrospective muhicentre survey in Germany and Switzerland. Oncology, 2010, 79 : 247-254.
  • 6Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma follow- ing an initial response to bortezomib. Am J Hematol, 2009,84: 657 -660.
  • 7Wolf J, Richardson PG, Schuster M, et al. Utility of bortezomib retreatment in relapsed or refractory muhiple myeloma patients: a muhicenter case series. Clin Adv Hematol Oncol, 2008,6 : 755- 760.
  • 8Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome in patients with t(4 ;14) myeloma but not outcome of patients with del (17p). Clin Oncol, 2010, 28:4630-4634.
  • 9Morgan GJ, Kaiser MF. How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Pro- gram,2012,2012:342-349.
  • 10Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and predni- sone in previously untreated multiple myeloma: updated follow- up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol, 2010,28:2259-2266.

共引文献114

同被引文献76

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部